Salt Lake City — It’s May 1, 2026, just past 11:03 MDT.
Recursion Pharmaceuticals announced that founder and board chair Chris Gibson won’t seek re-election at this year’s annual meeting, marking another step back from direct oversight after he exited the chief executive role a few months ago. CEO Najat Khan insisted the company stays committed to “continuity and long-term value creation.” Gibson described his time building Recursion as “one of the most rewarding journeys.” Recursion Pharmaceuticals, Inc.
Timing’s key here: Recursion releases its first-quarter numbers on May 6, ahead of the bell. Investors want specifics—cash burn, updated clinical schedules, and signs that its AI drug discovery tech is yielding tangible results. The company’s scheduled its public earnings call for 8:00 a.m. ET that morning.
Gibson notified Recursion on April 28 that he won’t seek another term as a Class II director, according to a filing. That seat rotates on a fixed schedule. The company said his move wasn’t triggered by any dispute over how things are run—no policy or procedural disagreement. Gibson is set to stay on as chair and a committee member through the end of his current term.
This latest board shuffle comes after a previous shakeup at the top. Back in November, Recursion announced Khan would step in as chief executive and president on Jan. 1. Gibson, meanwhile, shifted from CEO to chairman and interim executive adviser. Rob Hershberg also took on new duties, becoming vice-chairman and lead independent director.
Recursion shareholders are expected to log in for the online meeting scheduled June 17 at noon Mountain Time. On the agenda: two Class II director positions, executive compensation, and whether to keep PricewaterhouseCoopers as auditor. The proxy notes there were roughly 524.6 million Class A shares and 5.3 million Class B shares outstanding as of the April 21 record date.
Recursion wrapped up last year with $753.9 million in cash, cash equivalents, and restricted cash on hand as of Dec. 31, projecting enough to keep operations going into early 2028 without seeking new funding. Fourth-quarter revenue jumped to $35.5 million, up sharply from $4.5 million in the same period last year. Net loss for the quarter shrank to $108.1 million from $178.9 million. Khan described the quarter as “an inflection point.” Recursion Pharmaceuticals, Inc.
REC-4881 is still front-and-center for investors watching Recursion. The drug candidate targets familial adenomatous polyposis, or FAP—a genetic disorder where patients develop hundreds to thousands of colon and rectal polyps, sharply raising their odds of colorectal cancer if left untreated.
Wall Street’s take on Recursion shows a slight bullish lean, but there’s no consensus. According to StockAnalysis, JPMorgan’s Priyanka Grover reiterated her Buy call on April 30, trimming her target to $10 from $11. The site also notes five analysts cover the stock, with an average price target sitting at $8.00.
Recursion was trading at $3.44 Friday afternoon, holding steady with a market cap near $1.54 billion. The stock remains solidly in high-risk biotech territory, not in the league of established drugmakers—the company hasn’t brought any commercial medicines to market so far.
Plenty of players are jostling for position. Reuters noted that Certara, Schrödinger, and Recursion are all leaning on AI to predict how drugs will act and whether they’re safe. Recursion, meanwhile, made its mark by snapping up Exscientia—a smaller competitor—in an all-stock deal worth $688 million, aimed at bolstering its own AI-driven drug discovery toolkit.
The downside hasn’t changed. Recursion laid it out in its annual report: no approved products on the market, zero product revenue so far, and more losses ahead. The company also flagged the possibility of needing a sizeable cash injection—meaning shareholders could see dilution, or the pace of its programs might have to drop.
So far, the board’s transition appears smooth, not rushed. Next week is crunch time for Khan, who needs to prove that cleaner leadership will actually deliver stronger execution.
